Mounjaro vs Zepbound: same molecule, different approval
Released · Last reviewed
Mounjaro and Zepbound are the same drug — tirzepatide, from Eli Lilly — approved under two different names for two different indications. The difference determines your insurance coverage and out-of-pocket cost.
Mounjaro and Zepbound both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Because Medicare and many commercial plans cover diabetes drugs but exclude weight-loss drugs, Mounjaro is often covered when Zepbound is not — even though the molecule is the same. Neither is a compounded product.
At a glance
| Attribute | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (identical) |
| Maker | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Weight management; obstructive sleep apnea |
| Trial evidence | SURPASS (diabetes) | SURMOUNT (weight) |
| List price/mo | ~$1,069 | ~$1,086 |
| Medicare | Covered for T2D | Excluded for weight loss |
Which one applies to you
You do not choose between Mounjaro and Zepbound as products — your diagnosis and your prescriber determine which one is appropriate. If you have type 2 diabetes, Mounjaro is the labeled product and is far more likely to be covered by insurance, including Medicare Part D. If you are treating obesity or obstructive sleep apnea without diabetes, Zepbound is the labeled product, but it faces the statutory Medicare weight-loss exclusion and variable commercial coverage. The molecule and its effects are identical; the label, the coverage, and the price pathway differ.
How compounded tirzepatide fits
Compounded tirzepatide is a separate, non-FDA-approved category that some telehealth programs offer at $199–$297/month, far below either brand’s list price. It carries none of the SURMOUNT or SURPASS trial evidence and is legally restricted after the 2025 shortage resolution. See our tirzepatide cost guide and compounded tirzepatide guide.
Sources
- FDA — Mounjaro and Zepbound labels (Drugs@FDA). accessdata.fda.gov
- SURMOUNT and SURPASS trial programmes, NEJM.
The numbers behind this page
Three questions to ask before acting on this comparison
Every price quoted in this comparison comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this comparison sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.